MARKER OF PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM LYMPHOMA AND USE THEREOF

摘要

Disclosed are a novel therapeutic method for primary malignant central nervous system lymphoma, a marker of primary malignant central nervous system lymphoma which can serve as an indicator of primary malignant central nervous system lymphoma for the development of diagnostics, and use of the marker. A marker gene of primary malignant central nervous system lymphoma for use in the diagnosis of primary malignant central nervous system lymphoma, comprising Integrin β1 or Laminin α3. A subject is determined to have primary malignant central nervous system lymphoma when the amount of the expression of the gene in the subject is higher than that in a normal person.